Possible Precipitation of Migraine Attacks with Prophylactic Treatment
The initiation of a prophylactic treatment in a migraine sufferer depends upon the stratification of the patient’s frequency of attacks and the disability they cause, as well as the patient’s acute consumption and comorbid diseases. We report on 14 patients who were among a group of 618 migraine suf...
Gespeichert in:
Veröffentlicht in: | European neurology 2009-01, Vol.61 (1), p.23-26 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 26 |
---|---|
container_issue | 1 |
container_start_page | 23 |
container_title | European neurology |
container_volume | 61 |
creator | Donnet, A. Vuillaume De Diego, E. Lanteri-Minet, M. |
description | The initiation of a prophylactic treatment in a migraine sufferer depends upon the stratification of the patient’s frequency of attacks and the disability they cause, as well as the patient’s acute consumption and comorbid diseases. We report on 14 patients who were among a group of 618 migraine sufferers who received a new preventative treatment. These 14 patients developed an increase in the frequency of their migraine attacks that was possibly induced by this new prophylactic treatment. The clinical description of the migraine attacks remained the same but the frequency of the attacks of migraine without aura was dramatically increased. This is, to our knowledge, the first description of a possible precipitation of attacks of migraine without aura with a prophylactic treatment. There is no link with a specific class of prophylactic treatment. We hypothesize that the migraine sufferers who experienced aggravation after the new prophylactic drug had been introduced had a paradoxical decrease in the induction threshold for cortical spreading depression (CSD). Mechanisms of such a decrease are unknown and are probably multifactorial, but changes in serotonin neurotransmission have been experimentally demonstrated to modify cortical excitability and favour CSD. The aggravation was described only for attacks without aura. However, with only 14 patients, it is not possible to predict whether suffering from that the type of migraine is a factor that predisposes a patient to aggravation. While additional cases are necessary, physicians should be aware of the possibility that prophylactic treatment may exacerbate migraine attacks. |
doi_str_mv | 10.1159/000165345 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20911669</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1619147891</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-516018d42c3739e75313b73c7c6887187f7cd2aa5671ff48eedf2b769fccca033</originalsourceid><addsrcrecordid>eNpd0E1LAzEQBuAgiq3Vg3eRxYPgYTWT7ObjWIpVoWIP9bykabZNu18mKdJ_b6TFgqdhhmeG4UXoGvAjQC6fMMbAcprlJ6gPGYFUSqCnqB_HWUoxIT104f06trnk4hz1QMhMMMn6aDxtvbfzyiRTZ7TtbFDBtk3Slsm7XTplG5MMQ1B645NvG1aRtd1qVykdrE5mzqhQmyZcorNSVd5cHeoAfY6fZ6PXdPLx8jYaTlJNGQlpDgyDWGREU06l4TkFOudUc82E4CB4yfWCKJUzDmWZCWMWJZlzJkuttcKUDtD9_m7n2q-t8aGordemqlRj2q0vCJYAjMkI7_7Bdbt1TfytAJlJEEBZRA97pF1MwZmy6JytldsVgIvfZIu_ZKO9PRzczmuzOMpDlBHc7MFGuaVxR7Df_wHYensf</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>194918136</pqid></control><display><type>article</type><title>Possible Precipitation of Migraine Attacks with Prophylactic Treatment</title><source>MEDLINE</source><source>Karger_医学期刊</source><source>Alma/SFX Local Collection</source><creator>Donnet, A. ; Vuillaume De Diego, E. ; Lanteri-Minet, M.</creator><creatorcontrib>Donnet, A. ; Vuillaume De Diego, E. ; Lanteri-Minet, M.</creatorcontrib><description>The initiation of a prophylactic treatment in a migraine sufferer depends upon the stratification of the patient’s frequency of attacks and the disability they cause, as well as the patient’s acute consumption and comorbid diseases. We report on 14 patients who were among a group of 618 migraine sufferers who received a new preventative treatment. These 14 patients developed an increase in the frequency of their migraine attacks that was possibly induced by this new prophylactic treatment. The clinical description of the migraine attacks remained the same but the frequency of the attacks of migraine without aura was dramatically increased. This is, to our knowledge, the first description of a possible precipitation of attacks of migraine without aura with a prophylactic treatment. There is no link with a specific class of prophylactic treatment. We hypothesize that the migraine sufferers who experienced aggravation after the new prophylactic drug had been introduced had a paradoxical decrease in the induction threshold for cortical spreading depression (CSD). Mechanisms of such a decrease are unknown and are probably multifactorial, but changes in serotonin neurotransmission have been experimentally demonstrated to modify cortical excitability and favour CSD. The aggravation was described only for attacks without aura. However, with only 14 patients, it is not possible to predict whether suffering from that the type of migraine is a factor that predisposes a patient to aggravation. While additional cases are necessary, physicians should be aware of the possibility that prophylactic treatment may exacerbate migraine attacks.</description><identifier>ISSN: 0014-3022</identifier><identifier>EISSN: 1421-9913</identifier><identifier>DOI: 10.1159/000165345</identifier><identifier>PMID: 18948696</identifier><identifier>CODEN: EUNEAP</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Adrenergic beta-Antagonists - adverse effects ; Adult ; Aged ; Anticonvulsants - adverse effects ; Antidepressive Agents - adverse effects ; Calcium Channel Blockers - adverse effects ; Ergotamine - adverse effects ; Female ; Humans ; Male ; Middle Aged ; Migraine Disorders - chemically induced ; Migraine Disorders - prevention & control ; Original Paper ; Serotonin Antagonists - adverse effects</subject><ispartof>European neurology, 2009-01, Vol.61 (1), p.23-26</ispartof><rights>2008 S. Karger AG, Basel</rights><rights>2008 S. Karger AG, Basel.</rights><rights>Copyright (c) 2008 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-516018d42c3739e75313b73c7c6887187f7cd2aa5671ff48eedf2b769fccca033</citedby><cites>FETCH-LOGICAL-c362t-516018d42c3739e75313b73c7c6887187f7cd2aa5671ff48eedf2b769fccca033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2422,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18948696$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Donnet, A.</creatorcontrib><creatorcontrib>Vuillaume De Diego, E.</creatorcontrib><creatorcontrib>Lanteri-Minet, M.</creatorcontrib><title>Possible Precipitation of Migraine Attacks with Prophylactic Treatment</title><title>European neurology</title><addtitle>Eur Neurol</addtitle><description>The initiation of a prophylactic treatment in a migraine sufferer depends upon the stratification of the patient’s frequency of attacks and the disability they cause, as well as the patient’s acute consumption and comorbid diseases. We report on 14 patients who were among a group of 618 migraine sufferers who received a new preventative treatment. These 14 patients developed an increase in the frequency of their migraine attacks that was possibly induced by this new prophylactic treatment. The clinical description of the migraine attacks remained the same but the frequency of the attacks of migraine without aura was dramatically increased. This is, to our knowledge, the first description of a possible precipitation of attacks of migraine without aura with a prophylactic treatment. There is no link with a specific class of prophylactic treatment. We hypothesize that the migraine sufferers who experienced aggravation after the new prophylactic drug had been introduced had a paradoxical decrease in the induction threshold for cortical spreading depression (CSD). Mechanisms of such a decrease are unknown and are probably multifactorial, but changes in serotonin neurotransmission have been experimentally demonstrated to modify cortical excitability and favour CSD. The aggravation was described only for attacks without aura. However, with only 14 patients, it is not possible to predict whether suffering from that the type of migraine is a factor that predisposes a patient to aggravation. While additional cases are necessary, physicians should be aware of the possibility that prophylactic treatment may exacerbate migraine attacks.</description><subject>Adrenergic beta-Antagonists - adverse effects</subject><subject>Adult</subject><subject>Aged</subject><subject>Anticonvulsants - adverse effects</subject><subject>Antidepressive Agents - adverse effects</subject><subject>Calcium Channel Blockers - adverse effects</subject><subject>Ergotamine - adverse effects</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Migraine Disorders - chemically induced</subject><subject>Migraine Disorders - prevention & control</subject><subject>Original Paper</subject><subject>Serotonin Antagonists - adverse effects</subject><issn>0014-3022</issn><issn>1421-9913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpd0E1LAzEQBuAgiq3Vg3eRxYPgYTWT7ObjWIpVoWIP9bykabZNu18mKdJ_b6TFgqdhhmeG4UXoGvAjQC6fMMbAcprlJ6gPGYFUSqCnqB_HWUoxIT104f06trnk4hz1QMhMMMn6aDxtvbfzyiRTZ7TtbFDBtk3Slsm7XTplG5MMQ1B645NvG1aRtd1qVykdrE5mzqhQmyZcorNSVd5cHeoAfY6fZ6PXdPLx8jYaTlJNGQlpDgyDWGREU06l4TkFOudUc82E4CB4yfWCKJUzDmWZCWMWJZlzJkuttcKUDtD9_m7n2q-t8aGordemqlRj2q0vCJYAjMkI7_7Bdbt1TfytAJlJEEBZRA97pF1MwZmy6JytldsVgIvfZIu_ZKO9PRzczmuzOMpDlBHc7MFGuaVxR7Df_wHYensf</recordid><startdate>20090101</startdate><enddate>20090101</enddate><creator>Donnet, A.</creator><creator>Vuillaume De Diego, E.</creator><creator>Lanteri-Minet, M.</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20090101</creationdate><title>Possible Precipitation of Migraine Attacks with Prophylactic Treatment</title><author>Donnet, A. ; Vuillaume De Diego, E. ; Lanteri-Minet, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-516018d42c3739e75313b73c7c6887187f7cd2aa5671ff48eedf2b769fccca033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adrenergic beta-Antagonists - adverse effects</topic><topic>Adult</topic><topic>Aged</topic><topic>Anticonvulsants - adverse effects</topic><topic>Antidepressive Agents - adverse effects</topic><topic>Calcium Channel Blockers - adverse effects</topic><topic>Ergotamine - adverse effects</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Migraine Disorders - chemically induced</topic><topic>Migraine Disorders - prevention & control</topic><topic>Original Paper</topic><topic>Serotonin Antagonists - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Donnet, A.</creatorcontrib><creatorcontrib>Vuillaume De Diego, E.</creatorcontrib><creatorcontrib>Lanteri-Minet, M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database (ProQuest)</collection><collection>Science Database (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>European neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Donnet, A.</au><au>Vuillaume De Diego, E.</au><au>Lanteri-Minet, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Possible Precipitation of Migraine Attacks with Prophylactic Treatment</atitle><jtitle>European neurology</jtitle><addtitle>Eur Neurol</addtitle><date>2009-01-01</date><risdate>2009</risdate><volume>61</volume><issue>1</issue><spage>23</spage><epage>26</epage><pages>23-26</pages><issn>0014-3022</issn><eissn>1421-9913</eissn><coden>EUNEAP</coden><abstract>The initiation of a prophylactic treatment in a migraine sufferer depends upon the stratification of the patient’s frequency of attacks and the disability they cause, as well as the patient’s acute consumption and comorbid diseases. We report on 14 patients who were among a group of 618 migraine sufferers who received a new preventative treatment. These 14 patients developed an increase in the frequency of their migraine attacks that was possibly induced by this new prophylactic treatment. The clinical description of the migraine attacks remained the same but the frequency of the attacks of migraine without aura was dramatically increased. This is, to our knowledge, the first description of a possible precipitation of attacks of migraine without aura with a prophylactic treatment. There is no link with a specific class of prophylactic treatment. We hypothesize that the migraine sufferers who experienced aggravation after the new prophylactic drug had been introduced had a paradoxical decrease in the induction threshold for cortical spreading depression (CSD). Mechanisms of such a decrease are unknown and are probably multifactorial, but changes in serotonin neurotransmission have been experimentally demonstrated to modify cortical excitability and favour CSD. The aggravation was described only for attacks without aura. However, with only 14 patients, it is not possible to predict whether suffering from that the type of migraine is a factor that predisposes a patient to aggravation. While additional cases are necessary, physicians should be aware of the possibility that prophylactic treatment may exacerbate migraine attacks.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>18948696</pmid><doi>10.1159/000165345</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-3022 |
ispartof | European neurology, 2009-01, Vol.61 (1), p.23-26 |
issn | 0014-3022 1421-9913 |
language | eng |
recordid | cdi_proquest_miscellaneous_20911669 |
source | MEDLINE; Karger_医学期刊; Alma/SFX Local Collection |
subjects | Adrenergic beta-Antagonists - adverse effects Adult Aged Anticonvulsants - adverse effects Antidepressive Agents - adverse effects Calcium Channel Blockers - adverse effects Ergotamine - adverse effects Female Humans Male Middle Aged Migraine Disorders - chemically induced Migraine Disorders - prevention & control Original Paper Serotonin Antagonists - adverse effects |
title | Possible Precipitation of Migraine Attacks with Prophylactic Treatment |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T19%3A11%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Possible%20Precipitation%20of%20Migraine%20Attacks%20with%20Prophylactic%20Treatment&rft.jtitle=European%20neurology&rft.au=Donnet,%20A.&rft.date=2009-01-01&rft.volume=61&rft.issue=1&rft.spage=23&rft.epage=26&rft.pages=23-26&rft.issn=0014-3022&rft.eissn=1421-9913&rft.coden=EUNEAP&rft_id=info:doi/10.1159/000165345&rft_dat=%3Cproquest_cross%3E1619147891%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=194918136&rft_id=info:pmid/18948696&rfr_iscdi=true |